KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Long-Term Investments (2017 - 2023)

Pacira BioSciences (PCRX) has 10 years of Long-Term Investments data on record, last reported at $2.4 million in Q4 2023.

  • For Q4 2023, Long-Term Investments fell 93.52% year-over-year to $2.4 million; the TTM value through Dec 2023 reached $2.4 million, down 93.52%, while the annual FY2023 figure was $2.4 million, 93.52% down from the prior year.
  • Long-Term Investments reached $2.4 million in Q4 2023 per PCRX's latest filing, down from $8.3 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $70.6 million in Q3 2019 and bottomed at $2.4 million in Q4 2023.
  • Average Long-Term Investments over 5 years is $27.6 million, with a median of $21.4 million recorded in 2019.
  • Peak YoY movement for Long-Term Investments: skyrocketed 1484.13% in 2019, then crashed 93.52% in 2023.
  • A 5-year view of Long-Term Investments shows it stood at $64.8 million in 2019, then crashed by 78.37% to $14.0 million in 2020, then skyrocketed by 149.45% to $35.0 million in 2021, then increased by 6.4% to $37.2 million in 2022, then plummeted by 93.52% to $2.4 million in 2023.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $2.4 million in Q4 2023, $8.3 million in Q1 2023, and $37.2 million in Q4 2022.